Litcius/Paper detail

Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial

Rolf D. Issels, Elfriede Noeßner, Lars H. Lindner, M. Schmidt, Markus Albertsmeier, Jean‐Yves Blay, Emanuel Stutz, Yujun Xu, Veit Buecklein, A. Altendorf-Hofmann, Sultan Abdel-Rahman, Ulrich Mansmann, Michael von Bergwelt‐Baildon, Thomas Knoesel

2021European Journal of Cancer25 citationsDOI

Topics & Concepts

MedicineFOXP3ChemotherapyOncologyInternal medicineHyperthermiaNeoadjuvant therapyCD8Immune systemSoft tissue sarcomaClinical trialSarcomaPathologyCancerImmunologyBreast cancerSarcoma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial | Litcius